METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement

METiS Therapeutics, a Boston-Shanghai AI company, in-licensed global rights to a pan-RAF inhibitor program from Korea’s Voronoi in a deal worth up to $482 million. METiS will pay only $1.7 million upfront, with provision for $480.5 million in milestone payments, plus royalties. In December 2021, METiS completed a $86 million Series A funding, exclusively from China investors. In May, the company joined the Shanghai Roche Accelerator, the first AI drug discovery company at the Accelerator. METiS will apply its AI and machine learning platforms to develop the Voronoi pan-RAF inhibitor. More details....

Share this with colleagues: